{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T20:09:52Z","timestamp":1793736592507,"version":"4.6.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"A grant from the Ministry of Health of the Russian Federation","award":["2018-9-25"],"award-info":[{"award-number":["2018-9-25"]}]},{"name":"A grant from the Ministry of Health of the Russian Federation","award":["2018-9-25"],"award-info":[{"award-number":["2018-9-25"]}]},{"name":"A grant from the Ministry of Health of the Russian Federation","award":["2018-9-25"],"award-info":[{"award-number":["2018-9-25"]}]},{"name":"A grant from the Ministry of Health of the Russian Federation","award":["2018-9-25"],"award-info":[{"award-number":["2018-9-25"]}]},{"name":"A grant from the Ministry of Health of the Russian Federation","award":["2018-9-25"],"award-info":[{"award-number":["2018-9-25"]}]},{"name":"A grant from the Ministry of Health of the Russian Federation","award":["2018-9-25"],"award-info":[{"award-number":["2018-9-25"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-025-02756-y","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T14:10:24Z","timestamp":1746799824000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Effects of empagliflozin on functional capacity, LV filling pressure, and cardiac reserves in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction: a randomized controlled open-label trial"],"prefix":"10.1186","volume":"24","author":[{"given":"Artem","family":"Ovchinnikov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Potekhina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasiia","family":"Filatova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Svirida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Zherebchikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fail","family":"Ageev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeny","family":"Belyavskiy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,9]]},"reference":[{"key":"2756_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jcmg.2017.08.007","volume":"11","author":"RS Vasan","year":"2018","unstructured":"Vasan RS, Xanthakis V, Lyass A, Andersson C, Tsao C, Cheng S, et al. Epidemiology of left ventricular systolic dysfunction and heart failure in the framingham study: an echocardiographic study over 3 decades. JACC Cardiovasc Imaging. 2018;11:1\u201311. https:\/\/doi.org\/10.1016\/j.jcmg.2017.08.007.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"8","key":"2756_CR2","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.cardfail.2019.05.007","volume":"25","author":"SM Dunlay","year":"2019","unstructured":"Dunlay SM, Givertz MM, Aguilar D, Allen LA, Chan M, Desai AS, et al. Type 2 diabetes mellitus and heart failure, a scientific statement from the american heart association and heart failure society of America. J Card Fail. 2019;25(8):584\u2013619. https:\/\/doi.org\/10.1016\/j.cardfail.2019.05.007.","journal-title":"J Card Fail"},{"issue":"3","key":"2756_CR3","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/ejhf.2403","volume":"24","author":"AM Jackson","year":"2022","unstructured":"Jackson AM, R\u00f8rth R, Liu J, Kristensen SL, Anand IS, Claggett BL, et al. Diabetes and prediabetes in patients with heart failure and preserved ejection fraction. Eur J Heart Fail. 2022;24(3):497\u2013509. https:\/\/doi.org\/10.1002\/ejhf.2403.","journal-title":"Eur J Heart Fail"},{"key":"2756_CR4","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.cjca.2018.02.026","volume":"34","author":"P Meagher","year":"2018","unstructured":"Meagher P, Adam M, Civitarese R, Bugyei-Twum A, Connelly KA. Heart failure with preserved ejection fraction in diabetes: mechanisms and management. Can J Cardiol. 2018;34:632\u201343. https:\/\/doi.org\/10.1016\/j.cjca.2018.02.026.","journal-title":"Can J Cardiol"},{"issue":"1","key":"2756_CR5","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12902-018-0328-1","volume":"19","author":"K Kuziemski","year":"2019","unstructured":"Kuziemski K, S\u0142omi\u0144ski W, Jassem E. Impact of diabetes mellitus on functional exercise capacity and pulmonary functions in patients with diabetes and healthy persons. BMC Endocr Disord. 2019;19(1):2. https:\/\/doi.org\/10.1186\/s12902-018-0328-1.","journal-title":"BMC Endocr Disord"},{"issue":"1","key":"2756_CR6","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1089\/jwh.2010.2123","volume":"20","author":"MR Janevic","year":"2011","unstructured":"Janevic MR, Janz NK, Connell CM, Kaciroti N, Clark NM. Progression of symptoms and functioning among female cardiac patients with and without diabetes. J Womens Health. 2011;20(1):107\u201315. https:\/\/doi.org\/10.1089\/jwh.2010.2123.","journal-title":"J Womens Health"},{"issue":"9","key":"2756_CR7","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/j.jacc.2006.02.005","volume":"47","author":"L Ingle","year":"2006","unstructured":"Ingle L, Reddy P, Clark AL, Cleland JG. Diabetes lowers six-minute walk test performance in heart failure. J Am Coll Cardiol. 2006;47(9):1909\u201310. https:\/\/doi.org\/10.1016\/j.jacc.2006.02.005.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"2756_CR8","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.jacc.2014.05.030","volume":"64","author":"BR Lindman","year":"2014","unstructured":"Lindman BR, D\u00e1vila-Rom\u00e1n VG, Mann DL, McNulty S, Semigran MJ, Lewis GD, et al. Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study. J Am Coll Cardiol. 2014;64(6):541\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2014.05.030.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"2756_CR9","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1161\/CIRCULATIONAHA.122.059785","volume":"146","author":"G Filippatos","year":"2022","unstructured":"Filippatos G, Butler J, Farmakis D, Zannad F, Ofstad AP, Ferreira JP, et al. Empagliflozin for heart failure with preserved left ventricular ejection fraction with and without diabetes. Circulation. 2022;146(9):676\u201386. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.059785.","journal-title":"Circulation"},{"issue":"9","key":"2756_CR10","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1007\/s00424-014-1619-7","volume":"467","author":"I Vrhovac","year":"2015","unstructured":"Vrhovac I, Balen Eror D, Klessen D, Burger C, Breljak D, Kraus O, et al. Localizations of Na(+)-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart. Pflugers Arch. 2015;467(9):1881\u201398. https:\/\/doi.org\/10.1007\/s00424-014-1619-7.","journal-title":"Pflugers Arch"},{"issue":"1","key":"2756_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12933-016-0489-z","volume":"16","author":"J Habibi","year":"2017","unstructured":"Habibi J, Aroor AR, Sowers JR, Jia G, Hayden MR, Garro M, et al. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovasc Diabetol. 2017;16(1):9. https:\/\/doi.org\/10.1186\/s12933-016-0489-z.","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"2756_CR12","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10557-017-6734-1","volume":"31","author":"N Hammoudi","year":"2017","unstructured":"Hammoudi N, Jeong D, Singh R, Farhat A, Komajda M, Mayoux E, et al. Empagliflozin improves left ventricular diastolic dysfunction in a genetic model of type 2 diabetes. Cardiovasc Drugs Ther. 2017;31(3):233\u201346. https:\/\/doi.org\/10.1007\/s10557-017-6734-1.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"1","key":"2756_CR13","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12933-016-0473-7","volume":"15","author":"H Kusaka","year":"2016","unstructured":"Kusaka H, Koibuchi N, Hasegawa Y, Ogawa H, Kim-Mitsuyama S. Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome. Cardiovasc Diabetol. 2016;15(1):157. https:\/\/doi.org\/10.1186\/s12933-016-0473-7.","journal-title":"Cardiovasc Diabetol"},{"issue":"12","key":"2756_CR14","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1002\/ejhf.1328","volume":"20","author":"S Pabel","year":"2018","unstructured":"Pabel S, Wagner S, Bollenberg H, Bengel P, Kov\u00e1cs \u00c1, Schach C, et al. Empagliflozin directly improves diastolic function in human heart failure. Eur J Heart Fail. 2018;20(12):1690\u2013700. https:\/\/doi.org\/10.1002\/ejhf.1328.","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"2756_CR15","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/nrcardio.2014.83","volume":"11","author":"BA Borlaug","year":"2014","unstructured":"Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2014;11(9):507\u201315. https:\/\/doi.org\/10.1038\/nrcardio.2014.83.","journal-title":"Nat Rev Cardiol"},{"issue":"4","key":"2756_CR16","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","volume":"29","author":"SF Nagueh","year":"2016","unstructured":"Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European association of cardiovascular imaging. J Am Soc Echocardiogr. 2016;29(4):277\u2013314. https:\/\/doi.org\/10.1016\/j.echo.2016.01.011.","journal-title":"J Am Soc Echocardiogr"},{"issue":"1","key":"2756_CR17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/ejhf.2333","volume":"24","author":"TA McDonagh","year":"2022","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC). With the special contribution of the heart failure association (HFA) of the ESC. Eur J Heart Fail. 2022;24(1):4\u2013131. https:\/\/doi.org\/10.1002\/ejhf.2333.","journal-title":"Eur J Heart Fail."},{"key":"2756_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","volume":"28","author":"RM Lang","year":"2015","unstructured":"Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging. J Am Soc Echocardiogr. 2015;28:1-39.e14. https:\/\/doi.org\/10.1016\/j.echo.2014.10.003.","journal-title":"J Am Soc Echocardiogr"},{"key":"2756_CR19","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1093\/ehjci\/jeu219","volume":"16","author":"DA Morris","year":"2015","unstructured":"Morris DA, Takeuchi M, Krisper M, K\u00f6hncke C, Bekfani T, Carstensen T, et al. Normal values and clinical relevance of left atrial myocardial function analysed by speckle-tracking echocardiography: multicentre study. Eur Heart J Cardiovasc Imaing. 2015;16:364\u201372. https:\/\/doi.org\/10.1093\/ehjci\/jeu219.","journal-title":"Eur Heart J Cardiovasc Imaing"},{"issue":"1","key":"2756_CR20","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1186\/s12872-020-01671-2","volume":"20","author":"E Belyavskiy","year":"2020","unstructured":"Belyavskiy E, Ovchinnikov A, Potekhina A, Ageev F, Edelmann F. Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: a randomized open-label pilot study. BMC Cardiovasc Disord. 2020;20(1):408. https:\/\/doi.org\/10.1186\/s12872-020-01671-2.","journal-title":"BMC Cardiovasc Disord"},{"issue":"9","key":"2756_CR21","doi-asserted-by":"publisher","first-page":"H1373","DOI":"10.1152\/ajpheart.00157.2013","volume":"305","author":"M Guazzi","year":"2013","unstructured":"Guazzi M, Bandera F, Pelissero G, Castelvecchio S, Menicanti L, Ghio S, et al. Tricuspid annular plane systolic excursion and pulmonary arterial systolic pressure relationship in heart failure: an index of right ventricular contractile function and prognosis. Am J Physiol Heart Circ Physiol. 2013;305(9):H1373\u201381. https:\/\/doi.org\/10.1152\/ajpheart.00157.2013.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"6","key":"2756_CR22","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/0002-9149(87)91189-1","volume":"59","author":"A Dabestani","year":"1987","unstructured":"Dabestani A, Mahan G, Gardin JM, Takenaka K, Burn C, Allfie A, Henry WL. Evaluation of pulmonary artery pressure and resistance by pulsed Doppler echocardiography. Am J Cardiol. 1987;59(6):662\u20138. https:\/\/doi.org\/10.1016\/0002-9149(87)91189-1.","journal-title":"Am J Cardiol"},{"issue":"5","key":"2756_CR23","doi-asserted-by":"publisher","first-page":"mjca028","DOI":"10.1093\/jmcb\/mjac028","volume":"14","author":"M Abudureyimu","year":"2022","unstructured":"Abudureyimu M, Luo X, Wang X, Sowers JR, Wang W, Ge J, Ren J, Zhang Y. Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics. J Mol Cell Biol. 2022;14(5):mjca028. https:\/\/doi.org\/10.1093\/jmcb\/mjac028.","journal-title":"J Mol Cell Biol."},{"issue":"2","key":"2756_CR24","doi-asserted-by":"publisher","first-page":"102417","DOI":"10.1016\/j.dsx.2022.102417","volume":"16","author":"JA Requena-Ib\u00e1\u00f1ez","year":"2022","unstructured":"Requena-Ib\u00e1\u00f1ez JA, Santos-Gallego CG, Rodriguez-Cordero A, Vargas-Delgado AP, Badim\u00f3n JJ. Empagliflozin improves quality of life in nondiabetic HFrEF patients. Sub-analysis of the EMPATROPISM trial. Diabetes Metab Syndr. 2022;16(2):102417. https:\/\/doi.org\/10.1016\/j.dsx.2022.102417.","journal-title":"Diabetes Metab Syndr."},{"issue":"4","key":"2756_CR25","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.5135","volume":"7","author":"M Gao","year":"2024","unstructured":"Gao M, Bhatia K, Kapoor A, Badimon J, Pinney SP, Mancini DM, et al. SGLT2 inhibitors, functional capacity, and quality of life in patients with heart failure: a systematic review and meta-analysis. JAMA Netw Open. 2024;7(4): e245135. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.5135.","journal-title":"JAMA Netw Open"},{"issue":"11","key":"2756_CR26","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/j.jacc.2021.07.014","volume":"78","author":"A Pandey","year":"2021","unstructured":"Pandey A, Shah SJ, Butler J, Kellogg DL Jr, Lewis GD, Forman DE, et al. Exercise intolerance in older adults with heart failure with preserved ejection fraction: JACC state-of-the-art review. J Am Coll Cardiol. 2021;78(11):1166\u201387. https:\/\/doi.org\/10.1016\/j.jacc.2021.07.014.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"2756_CR27","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1093\/eurheartj\/ehaa943","volume":"42","author":"WT Abraham","year":"2021","unstructured":"Abraham WT, Lindenfeld J, Ponikowski P, Agostoni P, Butler J, Desai AS, et al. Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. Eur Heart J. 2021;42(6):700\u201310. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa943.","journal-title":"Eur Heart J"},{"issue":"7","key":"2756_CR28","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s00228-024-03660-2","volume":"80","author":"M Tanashat","year":"2024","unstructured":"Tanashat M, Manasrah A, Abouzid M. Effects of dapagliflozin and empagliflozin on 6-min walk distance in heart failure with preserved and reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials involving 2624 patients. Eur J Clin Pharmacol. 2024;80(7):951\u201363. https:\/\/doi.org\/10.1007\/s00228-024-03660-2.","journal-title":"Eur J Clin Pharmacol"},{"issue":"11","key":"2756_CR29","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.118.005254","volume":"11","author":"HJ Warraich","year":"2018","unstructured":"Warraich HJ, Kitzman DW, Whellan DJ, Duncan PW, Mentz RJ, Pastva AM, et al. Physical function, frailty, cognition, depression, and quality of life in hospitalized adults \u226560 years with acute decompensated heart failure with preserved versus reduced ejection fraction. Circ Heart Fail. 2018;11(11): e005254. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.118.005254.","journal-title":"Circ Heart Fail"},{"issue":"12","key":"2756_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2024.101395","volume":"3","author":"O Zainul","year":"2024","unstructured":"Zainul O, Marshall D, Lau JD, Kelly B, Zarzuela K, Damluji A, et al. Comparison of physical frailty assessments in heart failure with preserved ejection fraction. JACC Adv. 2024;3(12): 101395. https:\/\/doi.org\/10.1016\/j.jacadv.2024.101395.","journal-title":"JACC Adv"},{"issue":"5","key":"2756_CR31","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.2337\/dc21-2434","volume":"45","author":"P Mone","year":"2022","unstructured":"Mone P, Lombardi A, Gambardella J, Pansini A, Macina G, Morgante M, et al. Empagliflozin improves cognitive impairment in frail older adults with type 2 diabetes and heart failure with preserved ejection fraction. Diabetes Care. 2022;45(5):1247\u201351. https:\/\/doi.org\/10.2337\/dc21-2434.","journal-title":"Diabetes Care"},{"issue":"1","key":"2756_CR32","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/jcsm.13393","volume":"15","author":"AJS Coats","year":"2024","unstructured":"Coats AJS, Butler J, Tsutsui H, Doehner W, Filippatos G, Ferreira JP, et al. Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-Preserved. J Cachexia Sarcopenia Muscle. 2024;15(1):412\u201324. https:\/\/doi.org\/10.1002\/jcsm.13393.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"2","key":"2756_CR33","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/ejhf.2747","volume":"25","author":"K Omote","year":"2023","unstructured":"Omote K, Verbrugge FH, Sorimachi H, Omar M, Popovic D, Obokata M, et al. Central haemodynamic abnormalities and outcome in patients with unexplained dyspnoea. Eur J Heart Fail. 2023;25(2):185\u201396. https:\/\/doi.org\/10.1002\/ejhf.2747.","journal-title":"Eur J Heart Fail"},{"issue":"17","key":"2756_CR34","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1161\/CIRCULATIONAHA.120.052503","volume":"143","author":"ME Nassif","year":"2021","unstructured":"Nassif ME, Qintar M, Windsor SL, Jermyn R, Shavelle DM, Tang F, et al. Empagliflozin effects on pulmonary artery pressure in patients with heart failure: results from the EMBRACE-HF trial. Circulation. 2021;143(17):1673\u201386. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.052503.","journal-title":"Circulation"},{"issue":"10","key":"2756_CR35","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1161\/CIRCULATIONAHA.123.065134","volume":"148","author":"BA Borlaug","year":"2023","unstructured":"Borlaug BA, Reddy YNV, Braun A, Sorimachi H, Omar M, Popovic D, et al. Cardiac and metabolic effects of dapagliflozin in heart failure with preserved ejection fraction: the CAMEO-DAPA trial. Circulation. 2023;148(10):834\u201344. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.065134.","journal-title":"Circulation"},{"issue":"4","key":"2756_CR36","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s10557-019-06892-y","volume":"33","author":"M Otagaki","year":"2019","unstructured":"Otagaki M, Matsumura K, Kin H, Fujii K, Shibutani H, Matsumoto H, et al. Effect of tofogliflozin on systolic and diastolic cardiac function in type 2 diabetic patients. Cardiovasc Drugs Ther. 2019;33(4):435\u201342. https:\/\/doi.org\/10.1007\/s10557-019-06892-y.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"9","key":"2756_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.875327","volume":"4","author":"H Zhou","year":"2022","unstructured":"Zhou H, Peng W, Li F, Wang Y, Wang B, Ding Y, et al. Effect of sodium\u2013glucose cotransporter 2 inhibitors for heart failure with preserved ejection fraction: a systematic review and meta-analysis of randomized clinical trials. Front Cardiovasc Med. 2022;4(9): 875327. https:\/\/doi.org\/10.3389\/fcvm.2022.875327.","journal-title":"Front Cardiovasc Med"},{"issue":"7","key":"2756_CR38","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s00392-023-02164-w","volume":"112","author":"JH Prochaska","year":"2023","unstructured":"Prochaska JH, J\u00fcnger C, Schulz A, Arnold N, M\u00fcller F, Heidorn MW, et al. Effects of empagliflozin on left ventricular diastolic function in addition to usual care in individuals with type 2 diabetes mellitus-results from the randomized, double-blind, placebo-controlled EmDia trial. Clin Res Cardiol. 2023;112(7):911\u201322. https:\/\/doi.org\/10.1007\/s00392-023-02164-w.","journal-title":"Clin Res Cardiol"},{"issue":"3","key":"2756_CR39","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s10554-021-02443-5","volume":"38","author":"M Ersb\u00f8ll","year":"2022","unstructured":"Ersb\u00f8ll M, J\u00fcrgens M, Hasbak P, Kj\u00e6r A, Wolsk E, Zerahn B, et al. Effect of empagliflozin on myocardial structure and function in patients with type 2 diabetes at high cardiovascular risk: the SIMPLE randomized clinical trial. Int J Cardiovasc Imaging. 2022;38(3):579\u201387. https:\/\/doi.org\/10.1007\/s10554-021-02443-5.","journal-title":"Int J Cardiovasc Imaging"},{"issue":"5","key":"2756_CR40","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.echo.2020.02.005","volume":"33","author":"K Bami","year":"2020","unstructured":"Bami K, Gandhi S, Leong-Poi H, Yan AT, Ho E, Zahrani M, et al. Effects of empagliflozin on left ventricular remodeling in patients with type 2 diabetes and coronary artery disease: echocardiographic substudy of the EMPA-HEART cardiolink-6 randomized clinical trial. J Am Soc Echocardiogr. 2020;33(5):644\u20136. https:\/\/doi.org\/10.1016\/j.echo.2020.02.005.","journal-title":"J Am Soc Echocardiogr"},{"issue":"1","key":"2756_CR41","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s10557-023-07469-6","volume":"39","author":"MS P\u00e9rez","year":"2025","unstructured":"P\u00e9rez MS, Rodr\u00edguez-Capit\u00e1n J, Requena-Ib\u00e1\u00f1ez JA, Santos-Gallego CG, Urooj Zafar M, Escolar G, et al. Rationale and design of the SOTA-P-CARDIA Trial (ATRU-V): sotagliflozin in HFpEF patients without diabetes. J Cardiovasc Drugs Ther. 2025;39(1):155\u201364. https:\/\/doi.org\/10.1007\/s10557-023-07469-6.","journal-title":"J Cardiovasc Drugs Ther"},{"issue":"9","key":"2756_CR42","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1161\/CIRCULATIONAHA.109.869628","volume":"120","author":"C Tsch\u00f6pe","year":"2009","unstructured":"Tsch\u00f6pe C, Paulus WJ. Is echocardiographic evaluation of diastolic function useful in determining clinical care? Doppler echocardiography yields dubious estimates of left ventricular diastolic pressures. Circulation. 2009;120(9):810\u201320. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.869628.","journal-title":"Circulation"},{"issue":"1","key":"2756_CR43","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12933-018-0775-z","volume":"17","author":"F Soga","year":"2018","unstructured":"Soga F, Tanaka H, Tatsumi K, Mochizuki Y, Sano H, Toki H, Matsumoto K, Shite J, Takaoka H, Doi T, Hirata KI. Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure. Cardiovasc Diabetol. 2018;17(1):132. https:\/\/doi.org\/10.1186\/s12933-018-0775-z.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2756_CR44","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12933-020-01175-5","volume":"20","author":"M Rau","year":"2021","unstructured":"Rau M, Thiele K, Hartmann NK, Schuh A, Altiok E, M\u00f6llmann J, et al. Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study. Cardiovasc Diabetol. 2021;20(1):6. https:\/\/doi.org\/10.1186\/s12933-020-01175-5.","journal-title":"Cardiovasc Diabetol"},{"issue":"12","key":"2756_CR45","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1136\/hrt.2010.212787","volume":"97","author":"BA Borlaug","year":"2011","unstructured":"Borlaug BA, Jaber WA, Ommen SR, Lam CS, Redfield MM, Nishimura RA. Diastolic relaxation and compliance reserve during dynamic exercise in heart failure with preserved ejection fraction. Heart. 2011;97(12):964\u20139. https:\/\/doi.org\/10.1136\/hrt.2010.212787.","journal-title":"Heart"},{"issue":"4","key":"2756_CR46","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/ggi.14363","volume":"22","author":"H Akasaka","year":"2022","unstructured":"Akasaka H, Sugimoto K, Shintani A, Taniuchi S, Yamamoto K, Iwakura K, et al. Effects of ipragliflozin on left ventricular diastolic function in patients with type 2 diabetes and heart failure with preserved ejection fraction: The EXCEED randomized controlled multicenter study. Geriatr Gerontol Int. 2022;22(4):298\u2013304. https:\/\/doi.org\/10.1111\/ggi.14363.","journal-title":"Geriatr Gerontol Int"},{"issue":"7","key":"2756_CR47","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jchf.2022.05.004","volume":"10","author":"JL Januzzi Jr","year":"2022","unstructured":"Januzzi JL Jr, Butler J, Zannad F, Filippatos G, Ferreira JP, Pocock SJ, et al. Prognostic implications of N-terminal Pro-B-type natriuretic peptide and high-sensitivity cardiac troponin T in EMPEROR-preserved. JACC Heart Fail. 2022;10(7):512\u201324. https:\/\/doi.org\/10.1016\/j.jchf.2022.05.004.","journal-title":"JACC Heart Fail"},{"issue":"6","key":"2756_CR48","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jacc.2017.06.016","volume":"70","author":"JL Januzzi Jr","year":"2017","unstructured":"Januzzi JL Jr, Butler J, Jarolim P, Sattar N, Vijapurkar U, Desai M, Davies MJ. Effects of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetes. J Am Coll Cardiol. 2017;70(6):704\u201312. https:\/\/doi.org\/10.1016\/j.jacc.2017.06.016.","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"2756_CR49","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","volume":"140","author":"S Verma","year":"2019","unstructured":"Verma S, Mazer CD, Yan AT, Mason T, Garg V, Teoh H, et al. Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial. Circulation. 2019;140(21):1693\u2013702. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.042375.","journal-title":"Circulation"},{"issue":"11","key":"2756_CR50","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1002\/ejhf.3036","volume":"25","author":"A Bayes-Genis","year":"2023","unstructured":"Bayes-Genis A, Docherty KF, Petrie MC, Januzzi JL, Mueller C, Anderson L, et al. Practical algorithms for early diagnosis of heart failure and heart stress using NT-proBNP: a clinical consensus statement from the heart failure association of the ESC. Eur J Heart Fail. 2023;25(11):1891\u20138. https:\/\/doi.org\/10.1002\/ejhf.3036.","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"2756_CR51","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1161\/CIRCULATIONAHA.111.085761","volume":"126","author":"M Guazzi","year":"2012","unstructured":"Guazzi M, Borlaug BA. Pulmonary hypertension due to left heart disease. Circulation. 2012;126(8):975\u201390. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.085761.","journal-title":"Circulation"},{"issue":"7","key":"2756_CR52","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/ejhf.664","volume":"19","author":"S Ghio","year":"2017","unstructured":"Ghio S, Guazzi M, Scardovi AB, Klersy C, Clemenza F, Carluccio E, et al. Different correlates but similar prognostic implications for right ventricular dysfunction in heart failure patients with reduced or preserved ejection fraction. Eur J Heart Fail. 2017;19(7):873\u20139. https:\/\/doi.org\/10.1002\/ejhf.664.","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"2756_CR53","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jamacardio.2024.1914","volume":"9","author":"YNV Reddy","year":"2024","unstructured":"Reddy YNV, Carter RE, Sorimachi H, Omar M, Popovic D, Alogna A, et al. Dapagliflozin and right ventricular-pulmonary vascular interaction in heart failure with preserved ejection fraction: a secondary analysis of a randomized clinical trial. JAMA Cardiol. 2024;9(9):843\u201351. https:\/\/doi.org\/10.1001\/jamacardio.2024.1914.","journal-title":"JAMA Cardiol"},{"key":"2756_CR54","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.redox.2017.06.009","volume":"13","author":"S Steven","year":"2017","unstructured":"Steven S, Oelze M, Hanf A, Kr\u00f6ller-Sch\u00f6n S, Kashani F, Roohani S, et al. The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats. Redox Biol. 2017;13:370\u201385. https:\/\/doi.org\/10.1016\/j.redox.2017.06.009.","journal-title":"Redox Biol"},{"issue":"13","key":"2756_CR55","doi-asserted-by":"publisher","first-page":"7274","DOI":"10.3390\/ijms25137274","volume":"25","author":"N Mylonas","year":"2024","unstructured":"Mylonas N, Nikolaou PE, Karakasis P, Stachteas P, Fragakis N, Andreadou I. Endothelial protection by sodium\u2013glucose cotransporter 2 inhibitors: a literature review of in vitro and in vivo studies. Int J Mol Sci. 2024;25(13):7274. https:\/\/doi.org\/10.3390\/ijms25137274.","journal-title":"Int J Mol Sci"},{"issue":"15","key":"2756_CR56","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1042\/CS20190585","volume":"133","author":"M Xue","year":"2019","unstructured":"Xue M, Li T, Wang Y, Chang Y, Cheng Y, Lu Y, et al. Empagliflozin prevents cardiomyopathy via sGC-cGMP-PKG pathway in type 2 diabetes mice. Clin Sci. 2019;133(15):1705\u201320. https:\/\/doi.org\/10.1042\/CS20190585.","journal-title":"Clin Sci"},{"issue":"2","key":"2756_CR57","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1093\/cvr\/cvaa123","volume":"117","author":"D Kolijn","year":"2021","unstructured":"Kolijn D, Pabel S, Tian Y, L\u00f3di M, Herwig M, Carrizzo A, et al. Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase G\u03b1 oxidation. Cardiovasc Res. 2021;117(2):495\u2013507. https:\/\/doi.org\/10.1093\/cvr\/cvaa123.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"2756_CR58","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12933-021-01322-6","volume":"20","author":"E Daud","year":"2021","unstructured":"Daud E, Ertracht O, Bandel N, Moady G, Shehadeh M, Reuveni T, Atar S. The impact of empagliflozin on cardiac physiology and fibrosis early after myocardial infarction in nondiabetic rats. Cardiovasc Diabetol. 2021;20(1):132. https:\/\/doi.org\/10.1186\/s12933-021-01322-6.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2756_CR59","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12933-023-01756-0","volume":"22","author":"CC Chung","year":"2023","unstructured":"Chung CC, Lin YK, Chen YC, Kao YH, Yeh YH, Trang NN, Chen YJ. Empagliflozin suppressed cardiac fibrogenesis through sodium\u2013hydrogen exchanger inhibition and modulation of the calcium homeostasis. Cardiovasc Diabetol. 2023;22(1):27. https:\/\/doi.org\/10.1186\/s12933-023-01756-0.","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"2756_CR60","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/ejhf.3101","volume":"26","author":"JP Ferreira","year":"2024","unstructured":"Ferreira JP, Butler J, Anker SD, Januzzi JL, Panova-Noeva M, Reese-Petersen AL, et al. Effects of empagliflozin on collagen biomarkers in patients with heart failure: findings from the EMPEROR trials. Eur J Heart Fail. 2024;26(2):274\u201384. https:\/\/doi.org\/10.1002\/ejhf.3101.","journal-title":"Eur J Heart Fail"},{"issue":"15","key":"2756_CR61","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","volume":"73","author":"CG Santos-Gallego","year":"2019","unstructured":"Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, Ishikawa K, Watanabe S, Picatoste B, et al. Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics. J Am Coll Cardiol. 2019;73(15):1931\u201344. https:\/\/doi.org\/10.1016\/j.jacc.2019.01.056.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2756_CR62","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1093\/cvr\/cvaa064","volume":"117","author":"M Packer","year":"2021","unstructured":"Packer M. Critical examination of mechanisms underlying the reduction in heart failure events with SGLT2 inhibitors: identification of a molecular link between their actions to stimulate erythrocytosis and to alleviate cellular stress. Cardiovasc Res. 2021;117(1):74\u201384. https:\/\/doi.org\/10.1093\/cvr\/cvaa064.","journal-title":"Cardiovasc Res"},{"issue":"11","key":"2756_CR63","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/s44161-023-00352-5","volume":"2","author":"CE Angermann","year":"2023","unstructured":"Angermann CE, Santos-Gallego CG, Requena-Ibanez JA, Sehner S, Zeller T, Gerhardt LMS, et al. Empagliflozin effects on iron metabolism as a possible mechanism for improved clinical outcomes in non-diabetic patients with systolic heart failure. J Nat Cardiovasc Res. 2023;2(11):1032\u201343. https:\/\/doi.org\/10.1038\/s44161-023-00352-5.","journal-title":"J Nat Cardiovasc Res"},{"key":"2756_CR64","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae917","author":"CE Angermann","year":"2025","unstructured":"Angermann CE, Sehner S, Gerhardt LMS, Santos-Gallego CG, Requena-Ibanez JA, Zeller T, et al. Anaemia predicts iron homoeostasis dysregulation and modulates the response to empagliflozin in heart failure with reduced ejection fraction: the EMPATROPISM-FE trial. Eur Heart J. 2025. https:\/\/doi.org\/10.1093\/eurheartj\/ehae917.","journal-title":"Eur Heart J."},{"issue":"1","key":"2756_CR65","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s44156-024-00051-2","volume":"11","author":"S Robinson","year":"2024","unstructured":"Robinson S, Ring L, Oxborough D, Harkness A, Bennett S, Rana B, et al. The assessment of left ventricular diastolic function: guidance and recommendations from the British society of echocardiography. Echo Res Pract. 2024;11(1):16. https:\/\/doi.org\/10.1186\/s44156-024-00051-2.","journal-title":"Echo Res Pract"},{"key":"2756_CR66","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/ehf2.12235","volume":"5","author":"LF Buckley","year":"2018","unstructured":"Buckley LF, Canada JM, Del Buono MG, Carbone S, Trankle CR, Billingsley H, et al. Low NT-proBNP levels in overweight and obese patients do not rule out a diagnosis of heart failure with preserved ejection fraction. ESC Heart Fail. 2018;5:372\u20138. https:\/\/doi.org\/10.1002\/ehf2.12235.","journal-title":"ESC Heart Fail"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02756-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-025-02756-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02756-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T14:10:25Z","timestamp":1746799825000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02756-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,9]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2756"],"URL":"https:\/\/doi.org\/10.1186\/s12933-025-02756-y","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,9]]},"assertion":[{"value":"19 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study complied with the Declaration of Helsinki and was approved by the Ethics Committee of the Institute of Clinical Cardiology (Moscow, Russia). All patients provided written informed consent before study enrollment. All the data were anonymized to prevent any potential breaches of patient privacy.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors provided consent for the publication of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"196"}}